Our attorneys recently advised Biohaven Pharmaceutical Holding Company, a privately held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways, on its successful completion of an oversubscribed $80 million private financing.
Biohaven holds a portfolio of multiple late-stage assets and the proceeds from this financing will be used to advance the company's late stage clinical programs in orphan neurologic indications and other trials in areas of large unmet medical needs.
“This represents a significant milestone,” Biohaven CEO Vlad Coric, MD commented. “We are pleased to welcome these new investors as partners in our company and our mission to bring novel treatments to patients suffering from unmet medical needs. With this financing, we have a strong financial foundation from which we can develop our late stage clinical pipeline and advance new therapies into clinical trials.”